Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities

Autor: Robert L. Jackson, Barbara Hunt, William B. White, Aruna Dabholkar, Saima Chohan

Publikováno v: American heart journal. 164(1)

Comprehensive safety evaluation of new drugs for noncardiac indications is needed in the area of cardiovascular (CV) outcomes, particularly in populations with high CV risk such as gout. Febuxostat is a potent nonpurine selective inhibitor of xanthin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::786dc99441c92c55fb6b9cba6b31afbf
https://pubmed.ncbi.nlm.nih.gov/22795277

Long-Term Safety of TAK-390MR, a PPI with a Novel Dual Delayed Release Formulation, in GERD Patients

Autor: Aruna Dabholkar, Peter Yu, Maria Paris

Publikováno v: American Journal of Gastroenterology. 103:S5-S6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d216171a2fa7f620e45e5fb0f0aab0b
https://doi.org/10.14309/00000434-200809001-00014

The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

Autor: Dabholkar, A. H.¹ (AUTHOR), Han, C.¹ (AUTHOR), Paris, M. M.¹ (AUTHOR), Perez, M. C.¹ (AUTHOR), Atkinson, S. N.¹ (AUTHOR), Peura, D. A.² (AUTHOR)

Publikováno v: Alimentary Pharmacology & Therapeutics. Feb2011, Vol. 33 Issue 3, p366-377. 12p. 1 Diagram, 6 Charts, 1 Graph.

ESOPHAGUS.

Publikováno v: American Journal of Gastroenterology (Springer Nature); Sep2008 Supplement, Vol. 103, pS1-S38, 37p, 10 Black and White Photographs, 1 Diagram, 21 Charts, 11 Graphs

PEDIATRICS.

Publikováno v: American Journal of Gastroenterology (Springer Nature); Sep2008 Supplement, Vol. 103, pS526-S537, 11p, 3 Charts, 3 Graphs